2025 Nuclear Medicine Radiopharmaceuticals 
Imaging Technology
NOVEMBER 7, 2024
Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures.
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
OCTOBER 14, 2024
The article was published October 10 in the Journal of Nuclear Medicine. These SSTRs can be targeted both with gallium-68 (Ga-68) imaging agents and therapeutic lutetium-177 (Lu-177) radiopharmaceuticals using a so-called theranostics approach. The full article is available here.
AuntMinnie
SEPTEMBER 25, 2024
Nuclear cardiologists could see significant reductions in Medicare reimbursements in 2025, according to a leading expert. Nuclear cardiologists need to be aware of the potential negative financial impact and plan accordingly, Phillips said. Despite a proposal by the U.S.
Imaging Technology
JUNE 13, 2024
milla1cf Thu, 06/13/2024 - 20:53 June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians, technologists, pharmacists, laboratory professionals, scientists and others earlier this week at its 2024 Annual Meeting in Toronto, Ontario. Themed “Innovate. Illuminate.”, Illuminate.”,
AuntMinnie
NOVEMBER 4, 2024
Centers for Medicare & Medicaid Services (CMS) 2025 Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective Payment System (HOPPS) final rules. Although the 2025 MPFS calls for an overall 2.9% The change to the MPFS conversion factor reflects the 0% update required by statute for 2025, the expiration of the 2.9%
Imaging Technology
JANUARY 5, 2024
milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.
Expert insights. Personalized for you.
97 
Let's personalize your content